<DOC>
	<DOCNO>NCT01088737</DOCNO>
	<brief_summary>This prospective , longitudinal , uncontrolled study follow-up 5 years.Patients undergone surgical excision lentigo maligna ( LM ) lentigo maligna melanoma ( LMM ) invite study . Eligible patient start treatment imiquimod 6 week excision , treatment last 12 week . Inflammatory reaction occurrence residual lesion document . The heal effect determine ( initial clearance rate ) 20 week start treatment imiquimod . All patient enrol ( =exposed imiquimod study ) follow 5 year recurrence LM LMM</brief_summary>
	<brief_title>Imiquimod Detect Residual Lesions Prevent Recurrence Lentigo Maligna</brief_title>
	<detailed_description>Imiquimod ( Aldara ) 5 % cream apply start 6 week post-surgery area within 5 cm treatment margin side original scar LM LMM excision . Time period removal stitch first administration imiquimod 4 week , correspondent approximate 6 week post surgery . Imiquimod cream apply daily . Each patient begin application 3x/week . After two week treatment inflammation response imiquimod assess . If minor inflammation detectable treatment area , dose schedule increase 5x/week . After four week treatment inflammation response assess . If still minor inflammation detectable , application extend daily use . An interruption treatment imiquimod cream consider severe local inflammatory reaction occur , severe systemic reaction apparent super-infection observe treatment area . The primary objective study investigate potential imiquimod 5 % cream eliminate possible subclinical lesion LM reside surgical excision determine long-term recurrence rate . Secondary objective study describe incidence subclinical residual lesion local skin reaction .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Lentigo</mesh_term>
	<mesh_term>Hutchinson 's Melanotic Freckle</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Age &gt; 18 year Having undergone surgical excision LM LMM Positive histological finding LM LMM ( positive histology primary excision ) History allergic reaction imiquimod excipients . Pregnancy , breastfeed plan pregnancy study woman childbearing potential use adequate contraception . Women child bear potential use highly effective method birth control define result low failure rate ( i.e . &lt; 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs , tubal ligation vasectomise partner History malignant melanoma metastasise metastasis could expect Other malignant tumour study treatment area ( exception actinic keratosis ( AK ) ) Lack ability willingness give inform consent Lack willingness personal study relate data collect , archive transmit accord protocol Anticipated nonavailability study visits/procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lentigo maligna</keyword>
	<keyword>melanoma</keyword>
	<keyword>imiquimod</keyword>
	<keyword>prevention</keyword>
</DOC>